Details

Autor(en) / Beteiligte

• Fung, Ellen B., PhD, RD
• Xu, Yan, MS
• Kwiatkowski, Janet L., MD, MSCE
• Vogiatzi, Maria G., MD
• Neufeld, Ellis, MD, PhD
• Olivieri, Nancy, MD
• Vichinsky, Elliott P., MD
• Giardina, Patricia J., MD

Titel

Relationship between Chronic Transfusion Therapy and Body Composition in Subjects with Thalassemia

Ist Teil von

• The Journal of pediatrics, 2010-10, Vol.157 (4), p.641-647.e2

Ort / Verlag

Maryland Heights, MO: Mosby, Inc

Erscheinungsjahr

2010

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Objective To measure body composition in patients with thalassemia and explore its relationship to abnormal growth and bone mass. Study design We conducted a cross-sectional, multicenter study. Fat, lean, and bone mineral density (BMD) were assessed with dual-energy x-ray absorptiometry. Medical history, food frequency, and physical activity questionnaires were conducted in 257 transfused patients with thalassemia (age, 23.7 ± 11 years [mean ± SD]; 51% male) compared with 113 non-transfused patients (21.3 ± 13 years; 44% male). Results Subjects with thalassemia were leaner compared with healthy American subjects from National Health and Nutrition Examination Survey III data. Transfused subjects had a higher percentage of body fat compared with non-transfused subjects after controlling for age, sex, and ethnicity; 11.8% of non-transfused pediatric subjects were considered underweight, significantly lower than National Health and Nutrition Examination Survey data ( P = .03). Hemoglobin level was positively related to lean mass ( P = .008). Body fat and lean mass were positive predictors for both height and BMD z -scores after adjustment for transfusion status, age, sex, ethnicity, calcium intake, and physical activity (all P < .001). Conclusion Although most adult patients with thalassemia had healthy body composition with rare obesity, young non-transfused patients appear at risk for being underweight. Optimizing physical activity and appropriate use of transfusion therapy may improve growth and bone health in these patients who are at-risk for being underweight.